Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

Yet, slimmers trying a new weight-loss pill called Sirona — so far available only as a trial on the NHS — are yet to report any major adverse side effects. The capsule, which is taken in the ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

A weight loss pill to suppress appetite has been shown to work in clinical trials. The daily pill, by the manufacturer of weight loss jabs, saw participants manage to lose 8% of their body weight ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Eli Lilly is the pharma company behind the experimental weight-loss pill orforglipron.Credit: Bloomberg Lilly’s phase 3 trial, involving 559 people with Type 2 diabetes, showed they lost about ...

The latest clinical trial for Eli Lilly’s weight-loss pill suggests it’s as strong as Ozempic — with no needles required. In an exclusive interview, Dan Skovronsky, the company’s chief ...

Shares of Eli Lilly jumped 16% Thursday morning after the pharmaceutical company released Phase 3 trial results for its oral weight-loss drug that "demonstrated statistically significant efficacy ...